IHC - CD 25

The test is performed on a tissue sample, usually obtained through a biopsy. The tissue is treated with specific antibodies that bind to the CD35 protein and are visualized under a microscope.

The risks related to this test mainly stem from the biopsy procedure required to obtain the tissue sample. These may include pain, infection, or bleeding at the biopsy site.

A positive result indicates the presence of the CD35 protein in the tissue sample. This could provide insights into immune responses and potentially inform the diagnosis of certain conditions.

A negative result means that the CD35 protein was not detected in the tissue sample. This could help rule out certain conditions.

The turnaround time for this test is generally 7 to 10 days, although this can vary depending on the lab.

If you get a positive result, your healthcare provider will discuss the results with you, including potential next steps for further testing or treatment.

Yes, there are no dietary restrictions before this test.

The presence of CD35 could potentially indicate a variety of conditions related to immune response and inflammation. Therefore, this test may contribute to the diagnosis of multiple conditions.

Coverage for this test will depend on your insurance provider and plan. It's best to check with your provider for specifics about coverage.

No specific preparation is required for this test.

No, this test requires a tissue sample that must be collected in a healthcare setting and then processed in a laboratory.

The test itself is not painful, but the biopsy procedure to obtain the tissue sample can cause some discomfort.

The test results can be influenced by the quality of the tissue sample and the methods used to process and analyze it.

There's no specific age limit for this test. It's performed based on clinical necessity and healthcare provider's judgement.

IHC is a reliable technique used to visualize specific proteins in tissue samples. However, like any diagnostic test, it's not 100% accurate. The results should be interpreted in the context of other clinical information.

This test can be performed during pregnancy if deemed necessary by a healthcare provider.

The IHC - CD 35 test requires a tissue sample, typically obtained via a biopsy.

Yes, the results of this test can provide valuable information that may assist healthcare providers in determining the appropriate treatment plan.

The side effects after taking this test are mostly related to the biopsy procedure. Some people might experience mild pain, bruising, or bleeding at the biopsy site.

Yes, having a pacemaker or any other implanted device does not interfere with the IHC - CD 35 test. However, please notify your healthcare provider about any implanted devices before undergoing the biopsy.

Your healthcare provider will interpret the results in the context of your overall health, symptoms, and medical history. Depending on the results, further diagnostic tests may be needed, or a treatment plan may be outlined.